Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of 295.04 billion. The enterprise value is 319.92 billion.
| Market Cap | 295.04B |
| Enterprise Value | 319.92B |
Important Dates
The last earnings date was Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Mar 11, 2025 |
Share Statistics
| Current Share Class | 1.91B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.93% |
| Shares Change (QoQ) | -0.57% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.15% |
| Float | 1.82B |
Valuation Ratios
The trailing PE ratio is 21.10 and the forward PE ratio is 17.21.
| PE Ratio | 21.10 |
| Forward PE | 17.21 |
| PS Ratio | 5.21 |
| PB Ratio | 6.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.77 |
| P/OCF Ratio | 15.41 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.19, with an EV/FCF ratio of 18.18.
| EV / Earnings | 22.88 |
| EV / Sales | 5.52 |
| EV / EBITDA | 13.19 |
| EV / EBIT | 16.48 |
| EV / FCF | 18.18 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.12 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 1.49 |
| Debt / FCF | 2.02 |
| Interest Coverage | 16.61 |
Financial Efficiency
Return on equity (ROE) is 30.81% and return on invested capital (ROIC) is 23.60%.
| Return on Equity (ROE) | 30.81% |
| Return on Assets (ROA) | 11.14% |
| Return on Invested Capital (ROIC) | 23.60% |
| Return on Capital Employed (ROCE) | 22.71% |
| Weighted Average Cost of Capital (WACC) | 6.33% |
| Revenue Per Employee | 752,973 |
| Profits Per Employee | 185,792 |
| Employee Count | 75,883 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid 2.39 billion in taxes.
| Income Tax | 2.39B |
| Effective Tax Rate | 14.59% |
Stock Price Statistics
The stock price has increased by +45.85% in the last 52 weeks. The beta is 0.46, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +45.85% |
| 50-Day Moving Average | 135.78 |
| 200-Day Moving Average | 117.01 |
| Relative Strength Index (RSI) | 59.06 |
| Average Volume (20 Days) | 108,102 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of 56.67 billion and earned 13.98 billion in profits. Earnings per share was 7.15.
| Revenue | 56.67B |
| Gross Profit | 43.05B |
| Operating Income | 19.01B |
| Pretax Income | 16.35B |
| Net Income | 13.98B |
| EBITDA | 23.47B |
| EBIT | 19.01B |
| Earnings Per Share (EPS) | 7.15 |
Balance Sheet
The company has 11.53 billion in cash and 35.46 billion in debt, with a net cash position of -23.92 billion.
| Cash & Cash Equivalents | 11.53B |
| Total Debt | 35.46B |
| Net Cash | -23.92B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 46.55B |
| Book Value Per Share | 24.18 |
| Working Capital | 3.18B |
Cash Flow
In the last 12 months, operating cash flow was 19.14 billion and capital expenditures -1.55 billion, giving a free cash flow of 17.60 billion.
| Operating Cash Flow | 19.14B |
| Capital Expenditures | -1.55B |
| Free Cash Flow | 17.60B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.97%, with operating and profit margins of 33.53% and 24.67%.
| Gross Margin | 75.97% |
| Operating Margin | 33.53% |
| Pretax Margin | 28.85% |
| Profit Margin | 24.67% |
| EBITDA Margin | 41.42% |
| EBIT Margin | 33.53% |
| FCF Margin | 31.05% |
Dividends & Yields
This stock pays an annual dividend of 3.97, which amounts to a dividend yield of 2.60%.
| Dividend Per Share | 3.97 |
| Dividend Yield | 2.60% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 55.91% |
| Buyback Yield | 3.93% |
| Shareholder Yield | 6.53% |
| Earnings Yield | 4.74% |
| FCF Yield | 5.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novartis AG has an Altman Z-Score of 3.81 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.81 |
| Piotroski F-Score | 7 |